We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMODX
RNS Number : 3350O
Omega Diagnostics Group PLC
29 January 2019
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
VISITECT(R) CD4 Advanced Disease test update
Successful manufacture of three validation batches
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has successfully manufactured three validation batches of its VISITECT(R) CD4 Advanced Disease test.
Finished devices were tested in India, Zimbabwe and the UK and results demonstrate that all three batches performed in line with the Company's design goal parameters. These validation batches prove we can manufacture at scale and are a requirement for obtaining a CE Mark.
As previously communicated, we continue to make good progress and expect to complete internal verification work and external performance evaluation of venous whole blood samples during February.
We have also made progress with planned external performance evaluations of finger prick samples as follows;
o Zimbabwe - performance evaluation on finger prick blood commenced at the end of December 2018 and is estimated to be 50% complete
o India - ethics approval has recently been granted with the evaluation expected to commence in February 2019
We also note the interest from organisations such as Unitaid that have recently launched an initiative to avert preventable deaths from advanced HIV disease.(1)
Colin King, Chief Executive of the Group, commented: "I am pleased to announce that we continue to deliver against our timeline for the VISITECT(R) CD4 Advanced Disease test. I am also encouraged by the outlook for this product as key stakeholders continue to engage with us about the sizeable opportunity once we bring the test to market."
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
(1) https://unitaid.org/news-blog/unitaid-launches-initiative-to-avert-deaths-from-advanced-hiv/#en
Contacts:
Omega Diagnostics Group PLC Tel: 01259 763 030 Bill Rhodes, Interim Non-Executive www.omegadiagnostics.com Chairman Colin King, Chief Executive Kieron Harbinson, Group Finance Mob: 07740 084452 Director finnCap Ltd Tel: 020 7220 0500 Geoff Nash/Kate Bannatyne (Corporate Finance) Camille Gochez (ECM) Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com Paul McManus Mob: 07980 541 893 Lianne Cawthorne Mob: 07584 391 303
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RESLFFEILIITFIA
(END) Dow Jones Newswires
January 29, 2019 02:00 ET (07:00 GMT)
1 Year Omega Diagnostics Chart |
1 Month Omega Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions